Skip to main content

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Active, not recruiting · Phase 3 · NCT05445778

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

At a glance

Research payments reported, 2025
$1.8M
U.S. investigators named
54
Sites paid
59
Planned or actual enrollment
520

About the trial

Sponsor
AbbVie (with GOG Foundation)
Tested
Mirvetuximab soravtansine plus Bevacizumab (drug), Bevacizumab (drug)
Dates
Started 2023-03-15; completion 2032-05
Results posted
Not yet

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

From ClinicalTrials.gov, last updated 2026-06-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $1.8M in research payments for this study in 2025 (282 payments).

Products named: Elahere

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.